Tocilizumab, with the common brand name Actemra, has been included in China’s latest version of diagnosis and treatment guidelines on COVID-19. In addition to Tocilizumab, Chloroquine Phosphate and some traditional Chinese medicines, as well as convalescent plasma therapy, have been included in the treatment guideline. The combination of traditional Chinese medicines and Western medicines has shown good results in the treatment of COVID-19. Statistics show that 90 per cent of the patients in Hubei Province have been treated with traditional Chinese medicines, Sun said. So far, 154 severe patients have received such treatment with good effect, according to Sun.

Source: The Express Tribune March 06, 2020 16:41 UTC